Catalent Expands Fill-Finish Capacity
Catalent completes purchase of biologics fill-finish and oral solid dose facility in Anagni, Italy
Catalent announced on Jan. 7, 2020 the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy. The sale was announced in June 2019.
Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.
The 28,000 square-meter (305,000 square-feet) facility offers aseptic liquid and powder filling for biologics and sterile products for multiple vial sizes, and primary and secondary packaging solutions, including serialization, to support product launches for oral solids, sterile, and biologics products. Catalent has also announced that it plans to make further investments in the site’s growth, the company reported in a press statement.
“The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” commented Alessandro Maselli, Catalent’s president and chief operating officer in the press statement. “Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimize program risk.”
Source: Catalent
